FR2534580A1 - Derives de phenyl-1 piperidino-2 propanol, leur preparation, et medicaments qui les contiennent - Google Patents

Derives de phenyl-1 piperidino-2 propanol, leur preparation, et medicaments qui les contiennent Download PDF

Info

Publication number
FR2534580A1
FR2534580A1 FR8217187A FR8217187A FR2534580A1 FR 2534580 A1 FR2534580 A1 FR 2534580A1 FR 8217187 A FR8217187 A FR 8217187A FR 8217187 A FR8217187 A FR 8217187A FR 2534580 A1 FR2534580 A1 FR 2534580A1
Authority
FR
France
Prior art keywords
group
mixture
added
formula
hydrogen atom
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
FR8217187A
Other languages
English (en)
French (fr)
Other versions
FR2534580B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html
Inventor
Alexander Wick
Jonathan Frost
Bernard Gaudilliere
Jean Bertin
Regis Dupont
Jean Rousseau
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Synthelabo SA
Original Assignee
Synthelabo SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synthelabo SA filed Critical Synthelabo SA
Priority to FR8217187A priority Critical patent/FR2534580A1/fr
Priority to AT83401939T priority patent/ATE24490T1/de
Priority to EP83401939A priority patent/EP0109317B1/fr
Priority to DE8383401939T priority patent/DE3368610D1/de
Priority to ES526381A priority patent/ES8405766A1/es
Priority to AR83294516A priority patent/AR241267A1/es
Priority to MX199087A priority patent/MX156053A/es
Priority to IE2405/83A priority patent/IE56085B1/en
Priority to IL69955A priority patent/IL69955A/xx
Priority to NO833705A priority patent/NO158461C/no
Priority to JP58190590A priority patent/JPS5989660A/ja
Priority to FI833713A priority patent/FI77448C/fi
Priority to HU833525A priority patent/HU190509B/hu
Priority to CA000438856A priority patent/CA1228855A/en
Priority to GR72667A priority patent/GR78949B/el
Priority to PT77488A priority patent/PT77488B/pt
Priority to ZA837598A priority patent/ZA837598B/xx
Priority to NZ205938A priority patent/NZ205938A/en
Priority to AU20111/83A priority patent/AU559698B2/en
Priority to DK470583A priority patent/DK164593C/da
Publication of FR2534580A1 publication Critical patent/FR2534580A1/fr
Application granted granted Critical
Publication of FR2534580B1 publication Critical patent/FR2534580B1/fr
Priority to US06/773,926 priority patent/US4690931A/en
Priority to CS913577A priority patent/CS357791A3/cs
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/004—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reaction with organometalhalides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/45—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by condensation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/51—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by pyrolysis, rearrangement or decomposition
    • C07C45/54—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by pyrolysis, rearrangement or decomposition of compounds containing doubly bound oxygen atoms, e.g. esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/63—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by introduction of halogen; by substitution of halogen atoms by other halogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
    • C07C45/68—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
    • C07C45/70—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form
    • C07C45/71—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form being hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
    • C07C49/80—Ketones containing a keto group bound to a six-membered aromatic ring containing halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
    • C07C49/82—Ketones containing a keto group bound to a six-membered aromatic ring containing hydroxy groups
    • C07C49/825—Ketones containing a keto group bound to a six-membered aromatic ring containing hydroxy groups all hydroxy groups bound to the ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
    • C07C49/84—Ketones containing a keto group bound to a six-membered aromatic ring containing ether groups, groups, groups, or groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)
FR8217187A 1982-10-13 1982-10-13 Derives de phenyl-1 piperidino-2 propanol, leur preparation, et medicaments qui les contiennent Granted FR2534580A1 (fr)

Priority Applications (22)

Application Number Priority Date Filing Date Title
FR8217187A FR2534580A1 (fr) 1982-10-13 1982-10-13 Derives de phenyl-1 piperidino-2 propanol, leur preparation, et medicaments qui les contiennent
AT83401939T ATE24490T1 (de) 1982-10-13 1983-10-04 Phenyl-1-piperidino-2-propanol-derivate, ihre herstellung und diese enthaltende arzneimittel.
EP83401939A EP0109317B1 (fr) 1982-10-13 1983-10-04 Dérivés de phényl-1 pipéridino-2 propanol, leur préparation, et médicaments qui les contiennent
DE8383401939T DE3368610D1 (en) 1982-10-13 1983-10-04 Phenyl-1-piperidino-2-propanol derivatives, their preparation and medicaments containing them
AR83294516A AR241267A1 (es) 1982-10-13 1983-10-11 Procedimiento para preparar derivados de 2-(4-bencil-1-piperidinil)-1-fenilalconoles y sus sales.
MX199087A MX156053A (es) 1982-10-13 1983-10-11 Procedimiento para preparar derivados de 1-fenil-2-piperidino-propanol
ES526381A ES8405766A1 (es) 1982-10-13 1983-10-11 Procedimiento para preparar derivados de fenil-1-piperidino-2-propanol
ZA837598A ZA837598B (en) 1982-10-13 1983-10-12 Therapeutically useful 1-phenyl-2-piperidinoalkanol derivatives
NO833705A NO158461C (no) 1982-10-13 1983-10-12 Analogifremgangsmaate for fremstilling av fenyl-piperidin-propanol-derivater.
JP58190590A JPS5989660A (ja) 1982-10-13 1983-10-12 １−フエニル−２−ピペリジノアルカノ−ル誘導体
IE2405/83A IE56085B1 (en) 1982-10-13 1983-10-12 1-phenyl-2-piperidinopropanol derivatives,their preparation and pharmaceutical compositions containing them
HU833525A HU190509B (en) 1982-10-13 1983-10-12 Process for production of 1-phenil-piperidino-propanole derivates and medical products consisting of them
CA000438856A CA1228855A (en) 1982-10-13 1983-10-12 Therapeutically useful 1-phenyl-2-(4- benzylpiperidino) alkanol derivatives
GR72667A GR78949B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1982-10-13 1983-10-12
PT77488A PT77488B (fr) 1982-10-13 1983-10-12 Procede de preparation de derives de phenyl-1-piperidino-2-propanol et de compositions pharmaceutiques les contenant
IL69955A IL69955A (en) 1982-10-13 1983-10-12 1-phenyl-2-piperidinoalkanol derivatives,their preparation and pharmaceutical compositions containing them
NZ205938A NZ205938A (en) 1982-10-13 1983-10-12 1-phenyl-2-piperidinoalkanol derivatives and pharmaceutical compositions
AU20111/83A AU559698B2 (en) 1982-10-13 1983-10-12 Pharmaceutical 4-benzyl-n-substituted piperidines
DK470583A DK164593C (da) 1982-10-13 1983-10-12 Analogifremgangsmaade til fremstilling af 1-phenyl-2-piperidinopropanolderivater
FI833713A FI77448C (fi) 1982-10-13 1983-10-12 Foerfarande foer framstaellning av terapeutiskt anvaendbara 1-fenyl-2-piperidinopropanolderivat.
US06/773,926 US4690931A (en) 1982-10-13 1985-09-09 Therapeutically useful 1-phenyl-2-piperidinoalkanol derivatives
CS913577A CS357791A3 (en) 1982-10-13 1991-11-25 1-phenyl-2-piperidinopropanol derivatives, process for their preparation and pharmaceutical compositions comprising thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR8217187A FR2534580A1 (fr) 1982-10-13 1982-10-13 Derives de phenyl-1 piperidino-2 propanol, leur preparation, et medicaments qui les contiennent

Publications (2)

Publication Number Publication Date
FR2534580A1 true FR2534580A1 (fr) 1984-04-20
FR2534580B1 FR2534580B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1985-05-17

Family

ID=9278253

Family Applications (1)

Application Number Title Priority Date Filing Date
FR8217187A Granted FR2534580A1 (fr) 1982-10-13 1982-10-13 Derives de phenyl-1 piperidino-2 propanol, leur preparation, et medicaments qui les contiennent

Country Status (22)

Country Link
US (1) US4690931A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP0109317B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JPS5989660A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AR (1) AR241267A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE24490T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU559698B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA1228855A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CS (1) CS357791A3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE3368610D1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK164593C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES8405766A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FI (1) FI77448C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR (1) FR2534580A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GR (1) GR78949B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HU190509B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IE (1) IE56085B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL69955A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MX156053A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (1) NO158461C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ205938A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (1) PT77488B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA837598B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2428675A (en) * 2005-07-29 2007-02-07 Arakis Ltd Ifenprodil derivatives

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2581993B1 (fr) * 1985-05-14 1988-03-18 Synthelabo Derives de (benzoyl-4 piperidino)-2 phenyl-1 alcanols, leur preparation et leur application en therapeutique
ZA864772B (en) * 1985-07-02 1987-02-25 Merrell Dow Pharma Novel chemical compounds
EP0232423A4 (en) * 1985-07-24 1987-12-09 Grelan Pharmaceutical Co Circulation improving agent.
JPS6345230A (ja) * 1986-04-01 1988-02-26 Central Glass Co Ltd ブロモベンゾトリフルオリドの製造方法
KR910006138B1 (ko) * 1986-09-30 1991-08-16 에자이 가부시끼가이샤 환상아민 유도체
JP2573195B2 (ja) * 1986-09-30 1997-01-22 エーザイ株式会社 環状アミン誘導体
FR2654341B1 (fr) * 1989-11-14 1994-09-23 Synthelabo Utilisation d'ifenprodil et de ses derives pour la fabrication de medicaments antipsychotiques.
HU221193B1 (en) * 1990-05-10 2002-08-28 Pfizer Neuroprotective indole, qinoline and benzoxazolone derivatives, pharmaceutical compositions comprising such compounds and process for producing them
FR2672286B1 (fr) * 1991-01-31 1994-11-18 Synthelabo Derives de 1-(4-chlorophenyl)-2-[4-(phenylmethyl)piperidin-1-yl]ethanol, leur preparation et leur application en therapeutique.
BR9205893A (pt) * 1991-04-18 1994-11-08 Pfizer Ésteres pró droga de 2-piperidino-1-alcanóis fenólicos
ES2060547B1 (es) * 1992-06-04 1995-06-16 Ferrer Int Mejoras en el objeto de la patente de invencion n/ 9201158 que se refiere a "procedimiento de obtencion de nuevos derivados de la 4-bencilpiperidina".
FR2694555A1 (fr) * 1992-08-05 1994-02-11 Synthelabo Procédé de péparation des énantiomères du 1-(4-chloro-2-hydroxyphényl)-2-[4-[(4-fluorophényl)méthyl]-piperidin-1-yl]éthanol.
FR2696741B1 (fr) * 1992-10-12 1994-11-25 Synthelabo Dérivés de 1-(4-chlorophényl)-2-[4-[(4-fluorophényl)méthyl]piperidin-1-yl] éthanol, leur préparation et leur application en thérapeutique.
FR2697251B1 (fr) * 1992-10-22 1994-12-02 Synthelabo N-oxydes de dérivés de 1-(4-chlorophényl)-2-[4-[(4-fluorophényl)méthyl] pipéridin-1-yl]éthanol, leur procédé de préparation et leur application en thérapeutique.
EP0666854B1 (en) * 1992-10-30 1997-03-26 Pfizer Inc. Neuroprotective 3,4-dihydro-2(1h)-quinolone compounds
FR2699534B1 (fr) * 1992-12-21 1995-02-03 Synthelabo Dérivés de alpha-thiényl-pipéridine-1-éthanol, leur préparation et leur application en thérapeutique.
FR2717080B1 (fr) * 1994-03-09 1996-12-13 Synthelabo Utilisation de l'éliprodil et de ses énantiomères pour la préparation de médicaments utiles dans le traitement des neuropathies périphériques et des maladies neurodégénératives centrales.
DE4410822A1 (de) * 1994-03-24 1995-09-28 Schering Ag Neue Piperidin-Derivate
US5710165A (en) * 1994-07-06 1998-01-20 Synthelabo Use of polyamine antagonists for the treatment of glaucoma
FR2722497B1 (fr) * 1994-07-13 1996-08-14 Synthelabo Esters de alpha-4-chlorophenyl)-4-(4-fluorophenyl)methyl) piperidine-1-ethanol, leur preparation et leur application en therapeutique
FR2722987B1 (fr) * 1994-07-29 1997-05-16 Synthelabo Utilisation de l'eliprodil et de ses enantiomeres pour la preparation de medicaments utiles dans la prevention des neuropathiesinduites par des agentsanticancereux
FR2728568B1 (fr) 1994-12-23 1997-04-11 Synthelabo Intermediaires de synthese des enantiomeres de l'eliprodil et leur procede de preparation
FR2733422B1 (fr) * 1995-04-28 1997-05-30 Synthelabo Compositions pharmaceutiques a base d'eliprodil et d'un agent thrombolytique et leur application en therapeutique
US5604244A (en) * 1995-06-07 1997-02-18 Alcon Laboratories, Inc. Intraocular irrigating solution containing a polyamine antagonist
FR2738567B1 (fr) * 1995-09-08 1997-10-17 Synthelabo Derives de alpha-phenylpiperidine-1-propanol, leur preparation et leur application en therapeutique
US6441047B2 (en) 1995-11-17 2002-08-27 Alcon Manufacturing Ltd.. Combination therapy for treating glaucoma
CA2237898A1 (en) * 1995-11-17 1997-05-29 Louis Desantis Jr. Combination therapy for treating glaucoma
JP2000507205A (ja) * 1996-01-02 2000-06-13 シンテラボ 眼の虚血障害の治療薬の製造のためのポリアミン部位拮抗物質の使用
DE69614577D1 (de) * 1996-11-06 2001-09-20 Alcon Lab Inc Polyamin-antagonisten enthaltende intraokulare irrigationslösung
WO1999000129A1 (en) * 1997-06-30 1999-01-07 Dreyer Evan B Calcium blockers to treat proliferative vitreoretinopathy
GB9804885D0 (en) 1998-03-06 1998-04-29 Merck Sharp & Dohme Therapeutic combination
KR20020002356A (ko) 1998-10-27 2002-01-09 제임스 에이. 아노 외부 망막 손상의 치료
US6200990B1 (en) 1998-12-21 2001-03-13 Alcon Laboratories, Inc. Neuroprotective agents having antioxidant and NMDA antagonist activity
US6956036B1 (en) 2000-03-17 2005-10-18 Alcon, Inc. 6-hydroxy-indazole derivatives for treating glaucoma
US6927233B1 (en) 2000-03-17 2005-08-09 Alcon, Inc. 5ht2 agonists for controlling IOP and treating glaucoma
US6660870B1 (en) 2000-03-17 2003-12-09 Alcon, Inc. 2-acylaminobenzimidazole derivatives for treating glaucoma
US7012090B1 (en) 2000-03-17 2006-03-14 Alcon, Inc. Pyranoindoles for treating glaucoma
US7005443B1 (en) * 2000-03-17 2006-02-28 Alcon, Inc. 5-Hydroxy indazole derivatives for treating glaucoma
US6806285B1 (en) 2000-03-17 2004-10-19 Alcon, Inc. 5-Hydroxyl indole derivatives for treating glaucoma
US20030119846A1 (en) * 2000-03-17 2003-06-26 Collier Jr Robert J. Compounds with 5-ht activity useful for controlling visual field loss
EP1674087A1 (en) 2000-10-02 2006-06-28 Pfizer Products Inc. Prophylactic use of n-methyl-d-aspartate (NMDA) antagonists
WO2004098807A1 (en) * 2000-11-21 2004-11-18 Barsplice Products, Inc. Method of making steel couplers for joining concrete reinforcing bars
WO2002057235A1 (fr) * 2001-01-18 2002-07-25 Takeda Chemical Industries, Ltd. Procede de preparation de composes de benzylpiperidine
US20030212107A1 (en) * 2001-05-10 2003-11-13 Kapin Michael A. R-reliprodil for treating glaucoma
BR0210238A (pt) * 2001-06-01 2004-07-20 Alcon Inc Novos análogos de aril-amino-propano e seu uso para o tratamento de glaucoma
DE60209486T2 (de) * 2001-06-01 2006-08-03 Alcon Inc. Pyranoindazole und ihre verwendung in der glaukombehandlung
CA2447156A1 (en) * 2001-06-01 2002-12-12 Alcon, Inc. Novel fused indazoles and indoles and their use for the treatment of glaucoma
US6884816B2 (en) * 2001-08-31 2005-04-26 Alcon, Inc. Hydroxy substituted fused naphthyl-azoles and fused indeno-azoles and their use for the treatment of glaucoma
US20040254230A1 (en) * 2001-12-03 2004-12-16 Ogidigben Miller J. Method for treating ocular hypertension
US20040110776A1 (en) * 2002-02-22 2004-06-10 Iok-Hou Pang Use of propentofylline to control intraocular pressure
AU2003233731A1 (en) * 2002-06-06 2003-12-22 Xavier Billot 1,5-disubstituted imidazolidin-2-one derivatives for use as ep4 receptor agonists in the treatment of eye and bone diseases
AU2003233729B2 (en) 2002-06-06 2007-10-04 Merck Frosst Canada Ltd 1,5-distributed pyrrolid-2-one derivatives for use as EP4 receptor agonists in the treatment of eye diseases such as glaucoma
EP1545517A1 (en) * 2002-08-28 2005-06-29 Merck Frosst Canada & Co. Oxazolidin-2-one and thiazolidin-2-one derivatives for use as ep4 receptor agonists in the treatment of glaucoma
US7528163B2 (en) * 2002-11-08 2009-05-05 Merck & Co. Inc. Ophthalmic compositions for treating ocular hypertension
US7196082B2 (en) 2002-11-08 2007-03-27 Merck & Co. Inc. Ophthalmic compositions for treating ocular hypertension
EP1562592A4 (en) * 2002-11-12 2009-01-21 Alcon Inc HISTONE DEACETYLASE INHIBITORS FOR THE TREATMENT OF DEGENERATIVE DISEASES OF THE EYE
US20080004311A1 (en) * 2002-11-12 2008-01-03 Alcon, Inc. Histone deacetylase inhibitors for treating degenerative diseases of the eye
US7053085B2 (en) 2003-03-26 2006-05-30 Merck & Co. Inc. EP4 receptor agonist, compositions and methods thereof
JP2006511556A (ja) * 2002-12-13 2006-04-06 アルコン，インコーポレイテッド 新規のベンゾピラン類似体及び緑内障の治療のためのそれらの使用
US20060148805A1 (en) * 2003-07-01 2006-07-06 Meng Hsin Chen Opthalmic compositions for treating ocular hypertension
AU2004268012B2 (en) * 2003-09-02 2008-11-20 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
CA2537430A1 (en) * 2003-09-04 2005-03-24 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
WO2005026128A1 (en) * 2003-09-04 2005-03-24 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
ATE473967T1 (de) * 2003-11-26 2010-07-15 Pfizer Prod Inc Aminopyrazolderivate als gsk-3-inhibitoren
US7476687B2 (en) * 2003-11-26 2009-01-13 Alcon, Inc. Substituted furo[2,3-g]indazoles for the treatment of glaucoma
US7129257B1 (en) 2003-12-15 2006-10-31 Alcon, Inc. Pyrazolo[3,4- e]benzoxazoles for the treatment of glaucoma
US7338972B1 (en) 2003-12-15 2008-03-04 Alcon, Inc. Substituted 1-alkylamino-1H-indazoles for the treatment of glaucoma
AR046890A1 (es) * 2003-12-15 2005-12-28 Alcon Inc [1,4] oxazino [2,3-g] indazoles sustituidos para el tratamiento del glaucoma.
AU2005237543B2 (en) * 2004-04-26 2011-02-10 Alcon, Inc. Statins for the treatment of ocular hypertension and glaucoma
WO2006020003A2 (en) 2004-07-20 2006-02-23 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
WO2006062839A1 (en) * 2004-12-08 2006-06-15 Alcon, Inc. Use of dioxindoindazoles and dioxoloindazoles for treating glaucoma
US20060293378A1 (en) * 2005-06-28 2006-12-28 Mcintire Gregory Method of lowering intraocular pressure
WO2007014462A1 (en) * 2005-08-03 2007-02-08 Merck Frosst Canada Ltd. Ep4 receptor agonist, compositions and methods thereof
GB2430433A (en) * 2005-09-21 2007-03-28 Arakis Ltd Preparation & purification of 1-[4-(4-benzyloxy)phenyl]-2-(4-benzylpiperidin-1-yl)-1-propanone, & use thereof in stereospecific preparation of ifenprodil
TW200744567A (en) * 2005-09-23 2007-12-16 Alcon Inc Phenylethylamine analogs and their use for treating glaucoma
AU2007227664A1 (en) * 2006-03-13 2007-09-27 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
JP2009541219A (ja) * 2006-06-12 2009-11-26 メルク エンド カムパニー インコーポレーテッド 高眼圧治療のための眼科組成物
CN100448846C (zh) * 2006-12-04 2009-01-07 清华大学 一种催化氢化酰基吡啶为取代哌啶化合物盐酸盐的方法
UY30883A1 (es) 2007-01-31 2008-05-31 Alcon Res Tapones punctales y metodos de liberacion de agentes terapeuticos
WO2010112615A1 (en) 2009-04-03 2010-10-07 Dsm Ip Assets B.V. Lysine derivatives functionalised with lipids
US8648198B2 (en) * 2011-01-19 2014-02-11 Cold Spring Harbor Laboratory Phenylethanolamine-based NMDA receptor antagonists
CA2968926C (en) 2014-11-25 2023-01-17 Izhar Halahmi Compositions and methods for delivering a bio-active agent or bio-active agents
EP3383429B1 (en) 2015-11-30 2020-10-14 INSERM - Institut National de la Santé et de la Recherche Médicale Nmdar antagonists for the treatment of tumor angiogenesis
CN108623491B (zh) * 2017-03-24 2020-12-22 联化科技股份有限公司 一种卤代苯甲酰胺化合物的制备方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR5733M (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * 1966-09-27 1968-01-22
FR2070102A1 (en) * 1969-10-01 1971-09-10 Continental Pharma 1 subst phenyl 2 amino ethanols useful as beta - adrenergic agents peripheral vasodilators and hypo-
FR2105119A1 (en) * 1970-09-29 1972-04-28 Synthelabo Analgesic piperidino ethanol deriv - 1-parabenzyloxyphenyl -2-4-benzylpiperidinoethanol
FR2163358A1 (en) * 1971-12-15 1973-07-27 Synthelabo Phenylalkanolamine derivs - with effects on the smooth musculature
FR2208901A1 (en) * 1972-12-04 1974-06-28 Rhone Poulenc Sa Alpha-(4-substd pyridino)-4-benzyloxypropiophenones - as inters for cardiovascular 1-(4-hydroxy-phenyl)-2-(4-substd piperidino) propan-1-ols
FR2471374A1 (fr) * 1979-12-07 1981-06-19 Cosmos Enterprise Nouveau procede pour la preparation du 1-(4-hydroxyphenyl)-2-(4-benzylpiperidino)-propanol et de ses sels d'addition d'acides

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1321701A (en) * 1969-10-01 1973-06-27 Continental Pharma Amino-alcohols their salts and process for prepairing the same
US3867455A (en) * 1970-06-02 1975-02-18 Allen & Hanburys Ltd Preparation of phenylaminoethanols
AT310146B (de) * 1971-04-26 1973-09-25 Boehringer Sohn Ingelheim Verfahren zur Herstellung von neuen N,N'-Bis-(β-hydroxyaryläthyl)-diaminoalkanen und deren Säureadditionssalzen
US3870715A (en) * 1972-03-09 1975-03-11 Nikolaus R Hansl Substituted amino ethyl meta benzoic acid esters
US4018825A (en) * 1972-07-27 1977-04-19 Warner-Lambert Company 5-Hydroxy-α-(substituted aminomethyl)-m-xylene-α,α'-diols
GB1390748A (en) * 1973-04-09 1975-04-16 Continental Pharma Alkyl and cycloalkylthiophenylalkylaminoalkanols their salts and the preparation thereof
US4011258A (en) * 1973-06-21 1977-03-08 Aktiebolaget Draco Orally active bronchospasmolytic compounds
IT1148741B (it) * 1980-11-28 1986-12-03 Zambeletti Spa L Procedimento per la preparazione dell'1-(3,5-dimetossi-4-idrossifenil)-2-(n-metilammino)etanolo cloridrato
FR2503705A1 (fr) * 1981-04-14 1982-10-15 Synthelabo Derives de phenethanolamine, leur preparation et leur application en therapeutique
JPS5896067A (ja) * 1981-12-01 1983-06-07 Hamari Yakuhin Kogyo Kk エリスロ１−（４−ヒドロキシフエニル）−２−（４−ベンジルピペリジノ）−１−プロパノ−ルの製造法およびその中間体

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR5733M (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * 1966-09-27 1968-01-22
FR2070102A1 (en) * 1969-10-01 1971-09-10 Continental Pharma 1 subst phenyl 2 amino ethanols useful as beta - adrenergic agents peripheral vasodilators and hypo-
FR2105119A1 (en) * 1970-09-29 1972-04-28 Synthelabo Analgesic piperidino ethanol deriv - 1-parabenzyloxyphenyl -2-4-benzylpiperidinoethanol
FR2163358A1 (en) * 1971-12-15 1973-07-27 Synthelabo Phenylalkanolamine derivs - with effects on the smooth musculature
FR2208901A1 (en) * 1972-12-04 1974-06-28 Rhone Poulenc Sa Alpha-(4-substd pyridino)-4-benzyloxypropiophenones - as inters for cardiovascular 1-(4-hydroxy-phenyl)-2-(4-substd piperidino) propan-1-ols
FR2471374A1 (fr) * 1979-12-07 1981-06-19 Cosmos Enterprise Nouveau procede pour la preparation du 1-(4-hydroxyphenyl)-2-(4-benzylpiperidino)-propanol et de ses sels d'addition d'acides

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2428675A (en) * 2005-07-29 2007-02-07 Arakis Ltd Ifenprodil derivatives

Also Published As

Publication number Publication date
ES526381A0 (es) 1984-06-16
CS357791A3 (en) 1992-04-15
NO833705L (no) 1984-04-16
FI833713A0 (fi) 1983-10-12
GR78949B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1984-10-02
DK164593B (da) 1992-07-20
ATE24490T1 (de) 1987-01-15
EP0109317A2 (fr) 1984-05-23
FI833713L (fi) 1984-04-14
ZA837598B (en) 1984-06-27
EP0109317B1 (fr) 1986-12-30
AU2011183A (en) 1984-04-19
AU559698B2 (en) 1987-03-19
FI77448C (fi) 1989-03-10
JPS5989660A (ja) 1984-05-23
JPS6158472B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1986-12-11
IL69955A0 (en) 1984-01-31
IL69955A (en) 1987-01-30
NZ205938A (en) 1985-11-08
FI77448B (fi) 1988-11-30
DK470583A (da) 1984-04-14
AR241267A1 (es) 1992-04-30
NO158461C (no) 1988-09-14
NO158461B (no) 1988-06-06
CA1228855A (en) 1987-11-03
MX156053A (es) 1988-06-22
IE832405L (en) 1984-04-13
FR2534580B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1985-05-17
HU190509B (en) 1986-09-29
EP0109317A3 (en) 1984-08-08
DK470583D0 (da) 1983-10-12
IE56085B1 (en) 1991-04-10
PT77488A (fr) 1983-11-01
PT77488B (fr) 1986-05-07
DE3368610D1 (en) 1987-02-05
ES8405766A1 (es) 1984-06-16
US4690931A (en) 1987-09-01
DK164593C (da) 1992-12-07

Similar Documents

Publication Publication Date Title
FR2534580A1 (fr) Derives de phenyl-1 piperidino-2 propanol, leur preparation, et medicaments qui les contiennent
CH651561A5 (fr) Derives des nor-tropane et granatane et leur procede de preparation.
FR2498601A1 (fr) Nouveaux chromannes substitues utiles notamment comme anti-inflammatoires
CA1306261C (fr) 1,4-dihydropyridines, leur procede de preparation et leur application comme medicaments
EP0101381B1 (fr) Trifluorométhylphényltétrahydropyridines à activité anorexigène, un procédé de préparation et compositions pharmaceutiques
EP0012643B1 (fr) Dérivés de la phényl-1 (pipéridyl-4)-3 propanone-1, procédés pour leur préparation, et médicaments les contenant
FR2581993A1 (fr) Derives de (benzoyl-4 piperidino)-2 phenyl-1 alcanols, leur preparation et leur application en therapeutique
EP0429341A2 (fr) Dérivés hétérocycliques, leur préparation et les médicaments les contenant
CH640837A5 (fr) Derives de l'imidazole.
CH635812A5 (fr) Cycloalcanones et cycloalcanols substitues en position 3 par un groupe 2-hydroxyphenyle substitue en position 4 et composition pharmaceutique les contenant.
LU83576A1 (fr) Nouveaux derives du 4h-1,2,4-triazole,leur preparation,leur application comme medicament,les compositions les renfermant et les intermediaires obtenus
EP0269599B1 (fr) 1H-Imidazoles substitués
FR2493147A1 (fr) Compositions pharmaceutiques contenant des pyranones substituees en position 6
FR2713641A1 (fr) Dérivés de l'épi-épibatidine.
BE854655A (fr) 9-hydroxyhexahydrobenzo (c) quinoleines et intermediaires de synthese
LU79767A1 (fr) Nouveaux 9-hydroxyhexahydrodibenzo(b,d)pyranes,leurs derives substitues en position 1,leur procede de preparation et medicament les contenant
FR2623188A1 (fr) Acides phenyl hydroxamiques comportant un substituant heteroatomique, a action therapeutique
BE868004A (fr) Derives de carbostyryle, leur procede de preparation et leurs applications en therapeutique
BE752627R (en) 2-(6-Methoxy-2-naphthyl) propionic acid prepns. - anti-pyretics, analgesics, anti-inflammatory agents
FR2464252A1 (fr) Aroylvinylpiperidinobutyrophenones, utiles notamment comme medicaments antipsychotiques, procede de leur preparation et produits nouveaux utiles comme intermediaires dans ce procede
CH626806A5 (en) 2-Amino-3-(-5- and -6-)benzoylphenylacetic acid derivatives and process for preparing them
FR2630113A2 (fr) Derives de ((piperidinyl-4)methyl)-2 tetrahydro-1,2,3,4 isoquinoleine, leur preparation et leur application en therapeutique
BE622101A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR2468592A1 (fr) Nouvelles (alkyl-4 aroyl-4 piperidino)-4 butyrophenones utiles notamment comme medicaments antipsychotiques, procedes et intermediaires, pour leur preparation et compositions therapeutiques et formes pharmaceutiques les contenant
BE829791A (fr) Ethers alkyliques substitues et phenyliques substitues et leurs procedes de preparation

Legal Events

Date Code Title Description
ST Notification of lapse